EUVIMEDEUVIMED entdecken
Crossref

Qingfeiyin decoction in idiopathic pulmonary fibrosis: Lung-targeted components and PI3K-AKT modulation

Yongqi Liu, Luyao Song, Shiyi Chen, Jiajia Li, Xionghua Peng, Jianhua Sun, Ying Tian, Chenggang Huang, Li-Kun Gong, Jing Chen

Journal of Ethnopharmacology · 2025

DOI: 10.1016/j.jep.2025.120071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ethnopharmacology, 2025. Verfasst von Yongqi Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China; Zhongshan Institute for Drug Discovery, Shanghai Institute …. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Proto-Oncogene Proteins c-akt, Idiopathic Pulmonary Fibrosis, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ETHNOPHARMACOLOGICAL RELEVANCE: Qingfeiyin decoction (QFY), a well-documented traditional Chinese medicine formula, is used to treat a variety of lung diseases. However, the effect of QFY on idiopathic pulmonary fibrosis (IPF) is still unclear. AIM OF THE STUDY: This study aimed to investigate the effect of QFY on IPF, identify its bioactive components, and reveal the possible mechanism. MATERIALS AND METHODS: A bleomycin-induced pulmonary fibrosis mouse model was established to evaluate the anti-IPF effects of QFY. The bioactive ingredients in QFY were identified by HPLC-MS, following which their in vitro effects were examined by the cell models of epithelial-to-mesenchymal transition, fibroblast-to-myofibroblast transition and macrophage polarization. Network pharmacology and clinical dataset (GSE110147) were integrated to predict the possible mechanism of the bioactive ingredients, which were verified by in vitro experiments, molecular docking and molecular dynamics simulation. RESULTS: QFY demonstrated dose-dependent amelioration of IPF pathological phenotypes. Oroxylin A (OA), Geniposide (GDS), Baicalin (BCL), and Genipin-1-gentiobioside (GG) were identified with significant lung tissue enrichment, where OA and BCL exhibited obvious improvement in EMT, FMT, and macrophage polarization experiments. Network pharmacology and bioinformatics analyses revealed the association of OA/GDS/BCL/GG with the PI3K-AKT signaling pathway, which were confirmed by their effects on the migration and apoptosis of A549 and HFL1 cells. Concurrently, molecular docking and molecular dynamics simulations demonstrated strong binding affinities of BCL and OA for p110α and p110γ subunits of PI3K. CONCLUSIONS: Our work demonstrates the potential of QFY in the treatment of IPF, which might due to the bioactive ingredients in the lung affecting the PI3K signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalProto-Oncogene Proteins c-aktIdiopathic Pulmonary FibrosisPhosphatidylinositol 3-KinasesLungAnimalsMiceHumansMolecular Docking SimulationMaleMice, Inbred C57BLSignal TransductionBleomycinDisease Models, AnimalEpithelial-Mesenchymal TransitionNetwork Pharmacology

Stichwörter der Autor:innen

BaicalinIdiopathic pulmonary fibrosisMolecular dockingMolecular dynamic simulationNetwork pharmacologyOroxylin aQingfeiyin

Substanzen

Drugs, Chinese HerbalProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesBleomycin

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, Chi…
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese A…
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. Electronic address: cghuang@simm.ac.cn.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. Electronic address: jingchen@simm.ac.cn.

Förderung

  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Liu, Y., Song, L., Chen, S., Li, J., Peng, X., Sun, J., Tian, Y., Huang, C., Gong, L. K., & Chen, J. (2025). Qingfeiyin decoction in idiopathic pulmonary fibrosis: Lung-targeted components and PI3K-AKT modulation. Journal of Ethnopharmacology. https://doi.org/10.1016/j.jep.2025.120071

Vancouver

Liu Y, Song L, Chen S, Li J, Peng X, Sun J, et al. Qingfeiyin decoction in idiopathic pulmonary fibrosis: Lung-targeted components and PI3K-AKT modulation. Journal of Ethnopharmacology. 2025. doi:10.1016/j.jep.2025.120071

BibTeX
@article{Liu2025,
  author = {Liu, Yongqi and Song, Luyao and Chen, Shiyi and Li, Jiajia and Peng, Xionghua and Sun, Jianhua and Tian, Ying and Huang, Chenggang and Gong, Li-Kun and Chen, Jing},
  title = {Qingfeiyin decoction in idiopathic pulmonary fibrosis: Lung-targeted components and PI3K-AKT modulation},
  journal = {Journal of Ethnopharmacology},
  year = {2025},
  doi = {10.1016/j.jep.2025.120071}
}
Kostenlos starten →